Biosimilar Development News
-
Celltrion Announces The Acquisition Of iQone Healthcare Switzerland, Further Building Its Expertise And Foothold In Europe
11/15/2024
Celltrion, a global biopharmaceutical leader, announced its acquisition of iQone Healthcare Switzerland, a specialty pharmaceutical company focused on distribution, sales, and marketing in Switzerland.
-
Beneva Unveils Its Proactive Prescription Drug Management Strategy
11/14/2024
Beneva’s proactive management of prescription drug costs has generated annual savings of over $71M for its group insurance partners and plan members thanks to a four-pronged strategy consisting of mandatory biosimilar transition, pharmaceutical agreements, a prior authorization program and step therapy.
-
#SaveBigWithBiosimilars Campaign Provides Sustainable Solutions For Employer-Sponsored Health Benefit Plans
11/14/2024
Biosimilars Canada has launched a new #SaveBigWithBiosimilars campaign to educate Canadian businesses about the benefits of adopting biosimilar transition policies for their employee health benefit plans.
-
Sandoz Opens New Device Development Center In Cambridge, UK
11/11/2024
Sandoz, the global leader in generic and biosimilar medicines, today announced the opening of a state-of-the-art device development center in Cambridge, UK. Located at Cambridge Science Park, the new facility will serve as a global hub for developing advanced drug delivery devices that support the extensive Sandoz pipeline of affordable medicines.
-
Henlius And SVAX Forge Strategic Partnership In The MENAT Market
11/8/2024
On the morning of November 7, at the 7th China International Import Expo (CIIE), Henlius (2696.HK) entered into a strategic collaboration with AL-TIRYAQ AL-KHALAWI Medical Company ("SVAX"), a subsidiary entity of Saudi Arabia's prominent family business group in the healthcare sector, the Fakeeh Family.
-
MilliporeSigma Invests $76 Million To Expand ADC Manufacturing For Novel Cancer Therapies
11/6/2024
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, today announced a $76 million expansion of its ADC manufacturing capabilities and capacity at its Bioconjugation Center of Excellence facility in St. Louis, Missouri. This investment will triple existing capacity and enhance the company’s contract development and manufacturing organization (CDMO) offering, reinforcing its commitment to clients and patients.
-
European Medicines Agency Confirms Acceptance Of Marketing Authorization Application For AvT05, A Proposed Biosimilar To Simponi® (golimumab)
11/4/2024
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT05, Alvotech’s proposed biosimilar to Simponi® (golimumab), a biologic used to treat several chronic inflammatory diseases.
-
AscellaHealth Releases Q3 2024 Specialty & Rare Pipeline Digest™: FDA-Approved Biosimilars Outpaces Cell And Gene Therapy Amid Complex Regulatory Challenges
10/22/2024
AscellaHealth, a global partner delivering customizable solutions to support the specialty pharmaceutical industry, today released its latest Specialty & Rare Pipeline Digest™, the industry’s most comprehensive digital resource of new, pending and upcoming specialty and rare disease drug launches, cell and gene therapies (CGTs) and biosimilars.
-
Alvotech And Teva Announce U.S. FDA Approval Of Additional Presentation Of SELARSDI™ (ustekinumab-aekn), Expanding Its Label To Include Further Indications Approved For Reference Product, Stelara® (ustekinumab)
10/22/2024
Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) in a new presentation, 130 mg/26 mL (5 mg/mL) solution in a single-dose vial for intravenous infusion.
-
Boan Reports Positive PK Similarity Study Results Of BA1104
10/21/2024
The phase I clinical study aimed to establish the pharmacokinetic (PK) similarity between Boan Biotech’s Nivolumab injection BA1104(previously code-named LY01015)and Opdivo was recently published online in BioDrugs.